Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: A post-hoc analysis of the BIGPRO1 trial
A Fontbonne, I Diouf, M Baccara-Dinet, E Eschwege, M-A Charles
Diabetes & Metabolism | MASSON EDITEUR | Published : 2009
The BIGPROI trial was supported by grants from INSERM and the Caisse nationale d'assurance inaladie des travailleurs salari. s (CNAMts), as well as by funds from Lipha Phan-naceuticals Ltd. The present analysis was supported by a grant from Merck Sante.